重大事件即時報告 8-K 2026-07-02

Unicycive Therapeutics 8-K披露第二季現金結餘約6,140萬美元

AI 繁中摘要

Unicycive Therapeutics（納斯達克代號：UNCY）於2026年7月2日提交8-K表格，披露截至2026年6月30日的第二季度初步現金狀況。公司期末現金結餘約6,140萬美元，該數據由管理層編製，未經獨立註冊會計師事務所審計或覆核。

是次披露屬自願性更新，旨在讓投資者了解公司最新的流動資金狀況。雖然文件中未有提及營運業績、收入或支出細節，但接近6,200萬美元的現金水平，對於一家處於研發階段的生物製藥公司而言，提供了一定的財務緩衝。投資者可解讀為公司在推進管線項目（如候選藥物）時，短期內資金壓力相對較低。

管理層並無在文件中發表展望評論，亦未提及任何重大業務變動或里程碑。由於該8-K僅屬其他事項披露，對股價的直接影響有限，但現金餘額正面或有助穩定市場情緒。投資者應密切留意後續10-Q季度報告，以獲得更完整的財務表現及業務進展資訊。

展開英文正文

false
 0001766140
 
 
 
 
 
 
 
 0001766140
 
 
 2026-07-02
 2026-07-02
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
DC 20549

 

FORM 8-K

 

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): July 2, 2026

  

Unicycive
Therapeutics, Inc.

(Exact
name of registrant as specified in its charter)

 

 
 Delaware

  
 001-40582
  
 81-3638692

 
 (State
 or other jurisdiction
  
  (Commission
 File Number)
  
 IRS
 Employer

 
 of
 incorporation or organization)
  
  
  
 Identification
 No.)

 
  

1975
W. El Camino Real, Suite 204

Mountain
View, CA 94040

(Address
of principal executive offices)

 

Registrant’s
telephone number, including area code: (650) 351-4495

 

(Former
name or former address, if changed since last report)

 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title of each class: 
  
 Trading Symbol(s) 
  
 Name of each exchange on which registered: 

 
 Common
 Stock 
  
 UNCY 
  
 Nasdaq
 Capital Market 

 

 

Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

 

☐Written
 communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

 

Emerging
growth company  ☒

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

  

 

 

 

 

Item
8.01 Other Events.

 

The
Company had an ending cash balance of approximately $61.4 million as of June 30, 2026.

 

The
preliminary results for the second quarter ended June 30, 2026, have been prepared by and are the responsibility of management. Neither
our independent registered public accounting firm, nor any other independent accountants, have audited, reviewed, compiled or performed
any procedures with respect to the preliminary results, nor have they expressed any opinion or any other form of assurance with respect
thereto.

 

 1

 

 

 

SIGNATURE

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

Dated:
        July 2, 2026

  

 
    
 UNICYCIVE
 THERAPEUTICS, INC.

 
  
  

 
  
 By:
 /s/
 Shalabh Gupta

 
  
  
 Shalabh
 Gupta

 
  
  
 Chief Executive Officer

 

 

 2